DocGo extends $26M share repurchase program expiration to Dec. 31, 2026
DocGo (DCGO) has announced an extension of its $26 million share repurchase program. The expiration date for the program has been moved from June 30, 2026, to December 31, 2026, with no other changes made. The program allows for common stock purchases through various methods and will be funded from cash, future cash flow, or borrowings.
DocGo (NASDAQ: DCGO) extends $26M share repurchase program to year-end 2026
DocGo (NASDAQ: DCGO) has extended its existing $26 million share repurchase program from June 30, 2026, to December 31, 2026. This allows the company more time to buy back up to $26 million of its common stock through various methods, including open market transactions and Rule 10b5-1 trading plans. The program can be modified or discontinued at any time, and repurchases may be funded from existing cash, future cash flow, or borrowings.
Enterprise value to EBITDA forward of DocGo Inc. – NASDAQ:DCGO
This page provides financial data for DocGo Inc. (NASDAQ: DCGO), specifically focusing on its enterprise value to EBITDA forward metric. It appears to be a financial data snippet from TradingView, offering a quick overview of this specific financial ratio for the company.
Price to book forward of DocGo Inc. – NASDAQ:DCGO
This article displays the "Price to book forward" value for DocGo Inc. (NASDAQ: DCGO). It is presented within the context of financial data available on TradingView for the healthcare services company. The specific numerical value for the metric is awaited.
Price to sales forward of DocGo Inc. – NASDAQ:DCGO
The article provides a table showing the "Price to sales forward" for DocGo Inc. (NASDAQ: DCGO). It lists the period, value, change, and percentage change for this financial metric. The content highlights that the data for DocGo Inc. is available on TradingView, within the Markets section for US stocks.
Price to earnings forward of DocGo Inc. – NASDAQ:DCGO
The article provides a financial overview of DocGo Inc. (NASDAQ:DCGO), specifically mentioning its price to earnings forward metric. It indicates that no trades have occurred for the stock on the Nasdaq Stock Market as of market close. The content is primarily a data page from TradingView, focusing on financial information for the company.
DocGo Inc (DCGO) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for DocGo Inc (DCGO), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that the company ranks 45th out of 76 in its industry, with analysts generally recommending a "Buy" trend. The article also includes expected revenue and EPS for upcoming quarters, along with a peer comparison.
DocGo Inc (DCGO) Institutional Confidence
DocGo Inc (DCGO) has an institutional shareholding score of 3.00, placing it 56th out of 76 in the Healthcare Providers & Services industry. The current institutional shareholding proportion is 43.34%, which reflects a 45.16% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.53% of shares outstanding.
DocGo shareholders approve reverse stock split and board nominees at annual meeting
DocGo Inc. shareholders approved a reverse stock split, the election of two Class II directors, Vina Leite and James M. Travers, and executive compensation at their 2026 Annual Meeting. They also ratified the appointment of Urish Popeck & Co., LLC as the independent auditor. Two other proposed amendments related to corporate opportunities and officer exculpation did not pass.
DocGo shareholders approve reverse stock split and board nominees at annual meeting
DocGo Inc. (NASDAQ:DCGO) shareholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-10, and also elected directors Vina Leite and James M. Travers at their 2026 Annual Meeting. Additionally, executive compensation was approved, and Urish Popeck & Co., LLC was ratified as the independent auditor. Other proposed amendments, including a waiver of corporate opportunities and an officer exculpation amendment, did not pass.
DocGo shareholders approve reverse stock split and board nominees at annual meeting
DocGo Inc. shareholders have approved a reverse stock split at a ratio between 1-for-5 and 1-for-10, along with the election of Vina Leite and James M. Travers as Class II directors. They also ratified the appointment of Urish Popeck & Co., LLC as the independent auditor and approved executive compensation. Two other proposed amendments concerning corporate opportunities and officer exculpation did not pass.
DocGo (NASDAQ: DCGO) holders OK reverse split and reject officer exculpation
DocGo (NASDAQ: DCGO) stockholders approved a reverse stock split authorization, director elections, and executive compensation on an advisory basis at their 2026 annual meeting. However, they rejected proposed charter amendments related to corporate opportunities and officer liability exculpation. The exact ratio of the reverse stock split (between 1-for-5 and 1-for-10) is left to the board's discretion, and the rejection of the charter amendments means existing fiduciary and liability structures remain in place.
DocGo Inc (DCGO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for DocGo Inc (DCGO), detailing its financial performance by region. For the reported period, the United States accounted for 83.26% of revenue with $268.25 million, while the United Kingdom contributed 16.74% with $53.94 million. The company has not yet disclosed relevant data for business segments or various fiscal quarters and years beyond what is shown.
DocGo Inc (DCGO) Valuation: PE, PB & Fair Value Analysis
DocGo Inc (DCGO) currently has a valuation score of 8.47, placing it 43rd out of 76 in the Healthcare Providers & Services industry. Its P/E ratio is -0.30, significantly below its recent high and above its recent low. Key valuation metrics such as P/B, P/S, and P/CF have not yet been disclosed by the company.
DocGo Inc (DCGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of DocGo Inc (DCGO), detailing its price momentum score, current trading range between support and resistance levels, and indicator readings. It shows that DocGo Inc's current price momentum score is 4.44, ranking 71 out of 76 in its industry. The technical indicators and moving averages predominantly suggest a "Sell" signal for the stock.
DocGo Inc (DCGO) Financial Health: Profitability & Balance Sheet Analysis
DocGo Inc (DCGO) currently has a financial score of 7.20, placing it 52nd out of 76 in the Healthcare Providers & Services industry, indicating stable financial status and high operating efficiency. The company reported a quarterly revenue of $75.55M, marking a 21.33% year-over-year decrease, and its net profit saw a 56.97% year-over-year decline. The article provides a breakdown of its financial health across several dimensions including quality of earnings, operational efficiency, growth potential, and shareholder returns, though some relevant data are yet to be disclosed.
DCGO: Transitioning to proactive, tech-enabled care, the company targets growth and profitability
DocGo (DCGO) is shifting its business model from emergency response to a technology-driven, proactive healthcare delivery system. This new strategy, which includes in-home, virtual, and transportation services and integrates SteadyMD and the Care Anywhere platform, is aimed at improving efficiency, margins, and fostering growth. Regulatory changes and payer partnerships are expected to support the company's path to profitability and long-term expansion.
DocGo (DCGO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary
DocGo (DCGO) presented at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026, highlighting its transition from emergency response to proactive care and transportation. The company detailed its integrated technology platform, which aids in efficient medical transportation and virtual care services, emphasizing the impact of the SteadyMD acquisition and their "Care Anywhere" platform on expanding their healthcare offerings and improving outcomes. They also discussed evolving payer dynamics and the role of AI in their clinical practices.
DocGo Launches Mobile Phlebotomy Services in South Florida
DocGo has introduced new mobile phlebotomy services in South Florida, allowing patients to get blood draws and specimen collection at their homes or workplaces. This expansion aims to enhance access to diagnostic testing by deploying trained phlebotomists who then transport samples to partner laboratories for analysis. The service integrates with DocGo's existing healthcare logistics platform, marking a continued scaling of its mobile clinical operations.
DocGo launches mobile phlebotomy services in southern Florida By Investing.com
DocGo Inc.'s PTI Health subsidiary has launched mobile phlebotomy services in southern Florida, expanding its relationship with a major national clinical laboratory. This expansion allows PTI Health to provide blood collection and at-home testing services, operating with a low capital investment model. Despite facing near-term profitability challenges, DocGo's stock is considered undervalued by InvestingPro, and the company recently reported exceeding Q1 2026 revenue expectations.
DocGo launches mobile phlebotomy services in southern Florida
DocGo Inc.'s PTI Health subsidiary has expanded its services by launching mobile phlebotomy in southern Florida, partnering with a major national clinical laboratory. This expansion, operating on a low capital investment model, aims to provide blood collection and at-home testing services, and comes as DocGo's stock is considered undervalued despite facing near-term profitability challenges. The company recently reported first-quarter 2026 revenues that exceeded expectations, leading Needham to reiterate its Buy rating.
At-home blood draws come to South Florida as DocGo expands
DocGo (Nasdaq: DCGO) has launched mobile phlebotomy services in South Florida through its subsidiary PTI Health by DocGo. This expansion includes an extended partnership with a major national clinical laboratory to provide services across the Southeast, leveraging Florida's significant older adult population. The company anticipates this new market will operate with a strong margin profile due to its low capital investment model, further strengthening DocGo's "healthcare at any address" portfolio.
DocGo Launches Mobile Phlebotomy Services in South Florida
DocGo Inc. has expanded its mobile phlebotomy services to South Florida through its subsidiary PTI Health by DocGo. This expansion involves an enhanced relationship with a major national clinical laboratory, positioning DocGo for growth in the Southeast. The service aims to provide convenient and accessible lab collection and testing, particularly benefiting the region's large older adult population.
DCGO - DocGo Inc Stock Price and Quote
This article provides a comprehensive overview of DocGo Inc. (DCGO) stock, including its current price, financial metrics, analyst ratings, and recent news. It details the company's market performance, key financial figures, and a history of news announcements and analyst actions, giving investors a snapshot of its market position and recent activities.
DocGo targets profitability as it pivots to mobile health, medical transport
The provided article content is empty. Therefore, a summary cannot be generated.
DocGo Announces Upcoming Participation at the Goldman Sachs 47th Annual Global Healthcare Conference
DocGo (Nasdaq: DCGO) announced that CEO Lee Bienstock will participate in a fireside chat and hold 1x1 meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th. A webcast of the event will be available on DocGo's investor relations website. DocGo is a leading provider of technology-enabled mobile health and medical transportation services, aiming to reshape healthcare delivery.
DocGo outlines $310M-$315M 2026 revenue outlook while targeting 75% mobile phlebotomy growth
DocGo (DCGO) presented its 2026 revenue guidance, projecting between $310 million and $315 million. The company aims for significant growth in its mobile phlebotomy services, targeting a 75% increase by 2026, alongside expanding its medical transportation segment. DocGo also anticipates profitability with an adjusted EBITDA of $40 million to $50 million by the same year.
How The DocGo (DCGO) Story Is Shifting As Transport Optimism Meets Lower Valuation Targets
DocGo's (DCGO) modeled fair value has been revised down from US$2.10 to US$1.87, reflecting a mixed outlook from analysts. While optimism surrounds its transport business, concerns about execution persist, leading to lower price targets like Stifel's US$2.50. The company recently updated its 2026 revenue guidance, repurchased shares, and is asking stockholders to vote on a potential reverse stock split and other proposals.
DocGo Targets Profitability as It Pivots to Mobile Health, Medical Transport
DocGo (DCGO) is transitioning from COVID-related services to focus on its core medical transportation and growing mobile health businesses, aiming for profitability by the second half of the year. CEO Lee Bienstock highlighted the company's Q1 performance with no COVID-related revenue, a 31.6% adjusted gross margin, and an adjusted EBITDA loss of $10.2 million, while also raising full-year revenue guidance to $300-$315 million. The company is actively pursuing cost-saving initiatives, leveraging AI, and expanding strategic partnerships to enhance efficiency and scale its care-in-the-home services.
US$1.87: That's What Analysts Think DocGo Inc. (NASDAQ:DCGO) Is Worth After Its Latest Results
Analysts have updated their forecasts for DocGo Inc. (NASDAQ:DCGO) following its recent quarterly results. While revenue expectations for 2026 were slightly raised, loss per share predictions were also moderately increased, leading to an 11% reduction in the average price target to US$1.87. The company's revenue growth is expected to slow significantly compared to its historical performance and the wider industry.
DocGo (NASDAQ: DCGO) Q1 2026 revenue falls, covenant worries emerge
DocGo (NASDAQ: DCGO) reported a significant decline in Q1 2026 revenue and a widening net loss, primarily due to the discontinuation of large municipal migrant-related contracts. The company also disclosed non-compliance with a minimum liquidity covenant from December 31, 2025, and is actively negotiating with its lender. Management has implemented cost-cutting and cash-preservation plans, including increased stock-based compensation and workforce reductions, believing these measures are sufficient to ensure its ability to continue as a going concern for the next 12 months.
DocGo (DCGO) price target decreased by 10.71% to 1.91
This article reports that the price target for DocGo (DCGO) has been decreased by 10.71%, bringing the new target to $1.91. No further details are provided regarding the reasons for this change or the entities that issued the revised target.
DocGo Inc. - Common Stock (NQ: DCGO
This article provides a list of recent press releases and news headlines concerning DocGo Inc. (DCGO), ranging from November 2023 back to April 2023. Key topics include several announcements of securities class action lawsuits against the company, quarterly earnings reports, certifications, new contracts, partnerships, and executive appointments. The stock price for DocGo Inc. is also displayed, showing a slight increase.
US$1.87: That's What Analysts Think DocGo Inc. (NASDAQ:DCGO) Is Worth After Its Latest Results
DocGo Inc. (NASDAQ:DCGO) shares fell after its latest quarterly results, leading analysts to update their forecasts. While revenue expectations for 2026 were slightly raised to US$306.3m, the projected loss per share widened to US$0.34. Consequently, the average price target for DocGo was cut by 11% to US$1.87, reflecting increased pessimism about the company's valuation.
DocGo (DCGO) CEO sees 15,644 RSU shares withheld for tax liability
DocGo Inc. CEO Lee Bienstock had 15,644 shares of common stock withheld at $0.59 per share on May 12, 2026, to cover tax liabilities from restricted stock units (RSUs). Following this transaction, Bienstock directly holds 2,801,826 shares. The RSUs were granted under the company's 2021 Stock Incentive Plan and are scheduled to vest in various installments through December 2028.
Strong demand for DocGo virtual care drives higher 2026 revenue target
DocGo Inc. (Nasdaq: DCGO) announced its first quarter 2026 financial results, revealing a revised and increased revenue outlook for the full year 2026 to $300-$315 million, up from previous guidance. This positive adjustment is attributed to strong demand and growth in its virtual care services, particularly through its subsidiary SteadyMD, and other core mobile health businesses. Despite a decline in overall Q1 revenue due to the winding down of migrant-related programs, revenue excluding these programs saw a significant increase, with the company focusing on achieving adjusted EBITDA profitability in the latter half of the year.
DocGo Inc. (DCGO) reports Q1 loss, beats revenue estimates
DocGo Inc. (DCGO) reported a Q1 loss but exceeded revenue estimates. This suggests the company is growing its top-line performance despite operating at a loss, which is common for companies in growth phases.
Needham Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $3
Needham has reiterated its Buy rating for DocGo (DCGO.US) and maintained its target price at $3. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
DocGo Q1 Earnings Call Highlights
DocGo reported first-quarter revenue of $75.6 million and an adjusted EBITDA loss of $10.2 million. The company raised its 2026 revenue outlook due to strong performance in virtual care, medical transportation, and mobile health services, despite pressures from fuel costs and labor investments. CEO Lee Bienstock highlighted the growth of SteadyMD and new contracts, while CFO Norman Rosenberg addressed the impact of migrant-related project wind-downs on previous revenue figures.
DocGo Announces First Quarter 2026 Results
DocGo Inc. announced its financial results for the first quarter ended March 31, 2026, reporting total revenue of $75.6 million, a decrease from $96.0 million in Q1 2025 primarily due to the wind-down of migrant-related programs. Excluding these programs, revenue increased by 19.3%. The company also increased its full-year 2026 revenue guidance to $300-$315 million, driven by strong demand for virtual care services and growth in core business verticals.
DocGo (DCGO) Q1 2026 Earnings Transcript
DocGo (DCGO) reported Q1 2026 revenue of $75.6 million, with a decline attributed to the wind-down of migrant-related projects, though non-migrant revenues increased by 24% year over year. Virtual care offering SteadyMD and mobile phlebotomy are experiencing rapid growth, leading to an increased full-year revenue guidance to $300 million to $315 million. While the company faces temporary margin pressures from increased fuel costs and early operational expansion inefficiencies, management maintained its adjusted EBITDA loss guidance of $5 million to $10 million, anticipating improvements in profitability in the second half of 2026.
Earnings call transcript: DocGo’s Q1 2026 results show revenue beat but EPS miss
DocGo (DCGO) reported Q1 2026 revenue of $75.6 million, exceeding forecasts, but an EPS loss of $0.15 missed expectations. Despite the EPS miss and a decline in year-over-year revenue due to migrant-related project wind-downs, the stock rose 3.81% in after-hours trading, indicating positive investor sentiment regarding future growth. The company raised its 2026 revenue guidance to $300-$315 million and is focusing on expanding its SteadyMD platform and mobile health services, expecting profitability by Q3 2026.
DocGo (DCGO) Q1 2026 Earnings Transcript
DocGo (DCGO) reported Q1 2026 revenues of $75.6 million, exceeding expectations due to strong performance in its core Medical Transportation and Mobile Health segments, offsetting declines from discontinued migrant-related projects. The company raised its full-year revenue guidance to $300-$315 million but maintained its adjusted EBITDA loss guidance of $5-$10 million, citing temporary margin pressures from increased fuel costs and early-stage labor investments for rapid growth in SteadyMD. DocGo's strategic alternatives review is ongoing, with updates to be provided as available, while it focuses on expanding its virtual care, mobile phlebotomy, and "CareGap" services.
DocGo (NASDAQ: DCGO) posts Q1 2026 loss but lifts full-year revenue outlook
DocGo (NASDAQ: DCGO) reported a Q1 2026 net loss of $16.7 million, up from an $11.1 million loss in the prior year, primarily due to higher operating and non-recurring costs. Despite a decrease in total revenue to $75.6 million from $96.0 million due to the wind-down of migrant-related programs, underlying revenue grew 19.3% when excluding those programs, driven by mobile health and virtual care services. The company raised its full-year 2026 revenue guidance to $300–$315 million but maintained its adjusted EBITDA outlook at negative $5–$10 million, citing increased hiring and fuel costs as pressures on profitability.
DocGo reports Q1 2026 revenue $75.6M, adjusted EBITDA ($10.2M) and raises 2026 revenue outlook
DocGo reported Q1 2026 revenue of $75.6 million and an adjusted EBITDA loss of $10.2 million, primarily due to the wind-down of migrant-related programs. Despite this, the company raised its full-year 2026 revenue guidance to $300–$315 million, driven by growth in its core mobile health services and medical transportation segments. Excluding migrant-related programs, revenue increased by 19.3%, with significant growth in Mobile Health Services and Medical Transportation Services.
Number of shareholders of DocGo Inc. – BOATS:DCGO
This article focuses on the number of shareholders for DocGo Inc. (DCGO) as presented by BOATS (Blue Ocean Alternative Trade System) on TradingView. It provides market data and financial information related to the company, indicating that the market for DCGO was closed at the time of the article. The content appears to be a stub or a section of a larger financial data platform.
DocGo Inc expected to post a loss of 9 cents a share - Earnings Preview
DocGo Inc (DCGO) is anticipated to report a loss of 9 cents per share, according to an earnings preview. This forecast is based on information from Refinitiv.
DocGo (Nasdaq:DCGO) - Stock Analysis
DocGo (Nasdaq:DCGO) is a mobile healthcare services company operating in the US and UK, currently trading at US$0.57, which analysts believe is significantly undervalued. The company faces risks including volatile share price and declining earnings, but recently raised earnings guidance for FY2026 and announced an expansion of its clinical workforce for GLP-1 weight loss care. DocGo also received a Nasdaq minimum bid price non-compliance notice but is evaluating options to regain compliance.
DocGo Announces Upcoming Participation at the 21st Annual Needham Technology, Media, & Consumer Conference
DocGo (Nasdaq: DCGO) announced that CEO Lee Bienstock will present at the 21st Annual Needham Technology, Media, & Consumer Conference on May 14, 2026. He will deliver a company presentation and participate in one-on-one meetings, with a webcast available on DocGo's investor relations website. The company is a leading provider of technology-enabled medical transportation and mobile health services.
DocGo Announces Upcoming Participation at the 21st Annual Needham Technology, Media, & Consumer Conference
DocGo Inc. announced that CEO Lee Bienstock will deliver a presentation at the 21st Annual Needham Technology, Media, & Consumer Conference on Thursday, May 14, from 11:45 AM to 12:25 PM Eastern Time. A webcast of the presentation will be available on the investor relations section of DocGo’s website. DocGo is a leading provider of technology-enabled medical transportation and mobile health services, aiming to reshape traditional healthcare with proactive care delivery.
